NCT07786636

Not Yet Recruiting

Assessment of Early GFR, Tubular Function and Pathology Chan...

Rede Optimus Hospitalar SA Source

Compare

Other study identifiers

Sponsor study identifier

RO-250206

Study Type

interventional

Estimated enrollment

50

Locations

0 countries

Sites

N/A

Timeline

Study Start

September 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

August 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

August 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The purpose of this clinical study is to better understand how renal denervation (RDN) affects kidney function, both shortly after and up to a year after the procedure. Renal denervation is a minimally invasive treatment used for patients with high blood pressure that does not respond well to medication ("resistant hypertension"). It works by reducing the activity of nerves that run along the arteries supplying the kidneys, which helps lower blood pressure. To understand how RDN affects the kidneys, we will measure kidney function in detail and analyse blood and urine samples collected before and after the procedure. This will help researchers see whether the procedure causes changes in the kidneys, and whether some of these changes are linked to better kidney health over time.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: not yet recruiting
Estimated enrollment: 50 participants
Study completion date: August 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 12, 2026
Actual (reported)
First Posted
August 26, 2026
Actual (reported)
Study Start
September 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 26, 2026
Status Verified: August 2026
Last Update Submitted: August 25, 2026

Conditions

Renal Denervation Therapy

Outcome Measures

Primary Outcomes (1)

Change of a specific protein score in urine between Baseline visit (Day 1) and 12 months follow-up visit
Change of a specific protein score in urine prior to standard of care index procedure and 12 months from index procedure. Samples will be stored until the last patient had the last visit. All measurements will be then done afterwards.
Baseline visit (Day 1) and 12 months follow-up visit

Study Arms (1)

Patients who will undergo a renal denervation procedure within their standard of care

OTHER

bio sample collection (blood, urine)

Diagnostic Test: blood sampling

Interventions

blood samplingDiagnostic test

Blood samples will be taken to examine the mGFR as parameter for kidney function

Patients who will undergo a renal denervation procedure within their standard of care

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

≥18 years
eGFR \>30 ml/min/1.73m2 (CKD stages 3b and less severe)

Sponsors & Collaborators

Rede Optimus Hospitalar SA
Research networklead

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Alexandra Greindl, Dr

CONTACT

+49 157 851 281 40 alexandra.greindl@redeoptimus.com

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 12, 2026

First Posted

August 26, 2026

Study Start

September 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

August 2028

Estimated

Not Yet Recruiting

NCT07018310

Micro Assays for HemATology Malignancies Antibody Treatment

Not ApplicableNot Yet Recruiting

NCT06532760

Identification of Sodium Channel Fragments as Serum Biomarkers of a Traumatic Central Nervous System Injury

Not ApplicableNot Yet Recruiting

NCT07411937

Kynurenine Concentrations During Pregnancy in Women With or Without Chronic Kidney Disease - A Prospective Multicenter Study

Not ApplicableNot Yet Recruiting

NCT07803055

Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease

Not ApplicableRecruiting

NCT06270524

Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target

Not ApplicableNot Yet Recruiting

NCT06976008

CMV-associated Immunomodulation in Renal Transplant Patients

Not ApplicableNot Yet Recruiting

Informed consent for study participation provided by the patient or the legal guardian

Patient information and consent to the processing of personal data

Stable therapy in the previous three months

All patients undergoing RDN for clinical indications

You may not qualify if:

Patients in emergency situations
Turbid urine sample on admission
Visible haematuria in the urine sample on admission
Pregnancy
Allergy to contrast media (visipaque, omnipaque, iohexol)
Any problem, which, in the investigator's opinion, might jeopardize the participant's compliance with the protocol.

Contact the study team to confirm eligibility.

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

August 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 26, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07786636
Data provider: ClinicalTrials.gov
Source updated: 2026-08-26
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:22:41 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Patients who will undergo a renal denervation procedure within their standard of care

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record